A Study of CS1002 in Subjects With Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CStone Pharmaceuticals

Criteria

Inclusion Criteria:

1. Subjects with histologically or cytologically confirmed advanced or metastatic solid tumor(s) for which no effective standard therapy is available or tolerable.

2. ECOG performance status of 0 or 1.

3. Life expectancy ≥12 weeks.

4. Subjects must have adequate organ function

5. Use of effective contraception

Exclusion Criteria:

1. Known brain metastasis or other CNS metastasis that is either symptomatic or untreated.

2. Subjects with active autoimmune diseases or history of autoimmune diseases.

3. Subjects with immunodeficiency or receiving systemic steroid therapy or any other immunosuppressive therapy within 14 days prior to the first dose of CS1002.

4. Subjects who received prior therapy with an anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., OX-40, CD137).

5. Subjects who had prior chemotherapy, targeted therapy, immunotherapy or any other anti cancer systemic treatment, within 14 days prior to the first dose of CS1002 or who has not recovered from adverse events due to prior therapy.

6. Receipt of major surgical procedure, wide field of radiation, local radiotherapy or radioactive agents within specified time frame prior to the first dose of CS1002.

7. Receipt of live vaccine within 28 days prior to the first dose of CS1002

8. Use of traditional medicinal herbal preparations within 7 days prior to the first dose of CS1002.

9. History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.

10. Known history of HIV.

11. Subjects with active Hepatitis B or C infection

12. Subjects with active tuberculosis infection.

13. Subjects with an active infection requiring systemic therapy.

14. History of organ transplantation.

15. History of alcoholism or drugs abuse.

16. History of severe hypersensitivity reactions to other mAbs.

17. Subjects with major cardiovascular diseases.

For more information regarding trial participation, please contact at [email protected]